ESR1 and breast carcinoma: Since 2020, guidelines by ASCO-CAP have mandated that breast cancer specimens with ≥1% positively staining cells by immunohistochemistry should be considered ER-positive, the concept of a subclass of low ER-positive (1–10%) has emerged.